Aljohani H,Alrubaish FS,Alghamdi WM,Al-Harbi F .2024 .Safety of linagliptin in patients with type 2 diabetes mellitus: A systematic review and metaanalysis of randomized clinical trials. Ther Innov Regul Sci, 58(4) : 622-633.
Bhutta ZA,Ul Haq Z and Basit A .2022 .Diabetes in Pakistan: Addressing the crisis. Lancet Diabetes Endocrinol, 10(5) : 309-310.
Caleyachetty R,Barber TM,Mohammed NI,Cappuccio FP,Hardy R,Mathur R,Banerjee A,Gill P,Daza-Arnedo R,Rico-Fontalvo JE,Pájaro-Galvis N,LealMartínez V,Abuabara-Franco E,Raad-Sarabia M,Montejo-Hernández J,Cardona-Blanco M,CabralesJuan J,Uparella-Gulfo I,Montiel LS .2021 .Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: A narrative review. Kidney Med, 3(6) : 1065-1073.
Hashimoto-Kameda R,Cho KY,Nomoto H,Nakamura A,Omori K,Nagai S,Edagawa S,Kawata S,Takeuchi J,Kameda H,Kurihara Y,Aoki S,Atsumi T,Miyoshi H T .2021 .Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). Diabetes Res Clin Pract, 180 : 109069.
Laffel LM,Danne T,Klingensmith GJ,Tamborlane WV,Willi S,Zeitler P,Neubacher D,Marquard J .2023 .Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): A multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. , 11(3) : 169-81.
Lazzaroni E,Ben Nasr M,Loretelli C,Pastore I,Plebani L,Lunati ME,Vallone L,Bolla AM,Rossi A,Montefusco L,Ippolito E,Berra C,D'Addio F,Zuccotti GV,Fiorina P .2021 .Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res, 171 : 105782.
Lee SJ,Lee KH,Oh HG,Seo HJ,Jeong SJ,Kim CH .2019 .Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitus and coronary artery disease. J Obes Metab Syndr., 28(4) : 254-61.
Lin WR,Liu KH,Ling TC,Wang MC,Lin WH .2023 .Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease. World J Diabetes, 14(4) : 352-63.
Mingrone G,Castagneto-Gissey L,Bornstein SR .2022 .New horizons: Emerging antidiabetic medications. J Clin Endocrinol Metab, 107(12) : e4333-e40.
Nagayama A,Inokuchi T,Ashida K,Inada C,Homma T,Miyazaki H,Adachi T,Iwata S,Motomura S,Nomura M .2024 .Kurume medical study group of internal medicine. assessing the metabolic and physical effects of combined dpp4 and sglt2 inhibitor therapy in patients with type-2 diabetes mellitus: An observational prospective pilot study. JMA J, 7(3) : 387-400.
Saisho Y .2020 .Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes Metab, 46(3) : 186-196.
Son C,Makino H,Kasahara M,Tanaka T,Nishimura K,Taneda S,Nishimura T,Kasama S,Ogawa Y,Miyamoto Y,Hosoda K Y .2021 .Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Diabetes Res Clin Pract, 180 : 109037.
Suzuki Y,Kaneko H,Okada A,Ohno R,Yokota I,Fujiu K,Jo T,Takeda N,Morita H,Node K,Yasunaga H,Komuro I .2024 .Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus. J Endocrinol Invest, 47(5) : 1261-70.